BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 34311771)

  • 1. MEK inhibition ameliorates social behavior phenotypes in a Spred1 knockout mouse model for RASopathy disorders.
    Borrie SC; Plasschaert E; Callaerts-Vegh Z; Yoshimura A; D'Hooge R; Elgersma Y; Kushner SA; Legius E; Brems H
    Mol Autism; 2021 Jul; 12(1):53. PubMed ID: 34311771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired instrumental learning in Spred1
    Borrie SC; Horner AE; Yoshimura A; Legius E; Kopanitsa MV; Brems H
    Genes Brain Behav; 2021 Jun; 20(5):e12727. PubMed ID: 33624414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.
    Witkowski L; Dillon MW; Murphy E; S Lebo M; Mason-Suares H
    Mol Genet Genomic Med; 2020 Apr; 8(4):e1180. PubMed ID: 32107864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between a Domain of the Negative Regulator of the Ras-ERK Pathway, SPRED1 Protein, and the GTPase-activating Protein-related Domain of Neurofibromin Is Implicated in Legius Syndrome and Neurofibromatosis Type 1.
    Hirata Y; Brems H; Suzuki M; Kanamori M; Okada M; Morita R; Llano-Rivas I; Ose T; Messiaen L; Legius E; Yoshimura A
    J Biol Chem; 2016 Feb; 291(7):3124-34. PubMed ID: 26635368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Legius syndrome, an Update. Molecular pathology of mutations in SPRED1.
    Brems H; Legius E
    Keio J Med; 2013; 62(4):107-12. PubMed ID: 24334617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenic Mutations Associated with Legius Syndrome Modify the Spred1 Surface and Are Involved in Direct Binding to the Ras Inactivator Neurofibromin.
    Führer S; Tollinger M; Dunzendorfer-Matt T
    J Mol Biol; 2019 Sep; 431(19):3889-3899. PubMed ID: 31401120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Insights into the SPRED1-Neurofibromin-KRAS Complex and Disruption of SPRED1-Neurofibromin Interaction by Oncogenic EGFR.
    Yan W; Markegard E; Dharmaiah S; Urisman A; Drew M; Esposito D; Scheffzek K; Nissley DV; McCormick F; Simanshu DK
    Cell Rep; 2020 Jul; 32(3):107909. PubMed ID: 32697994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1.
    Stowe IB; Mercado EL; Stowe TR; Bell EL; Oses-Prieto JA; Hernández H; Burlingame AL; McCormick F
    Genes Dev; 2012 Jul; 26(13):1421-6. PubMed ID: 22751498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia.
    Pasmant E; Gilbert-Dussardier B; Petit A; de Laval B; Luscan A; Gruber A; Lapillonne H; Deswarte C; Goussard P; Laurendeau I; Uzan B; Pflumio F; Brizard F; Vabres P; Naguibvena I; Fasola S; Millot F; Porteu F; Vidaud D; Landman-Parker J; Ballerini P
    Oncogene; 2015 Jan; 34(5):631-8. PubMed ID: 24469042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moyamoya syndrome in a child with Legius syndrome: Introducing a cerebral vasculopathy to the SPRED1 phenotype?
    Pabst L; Carroll J; Lo W; Truxal KV
    Am J Med Genet A; 2021 Jan; 185(1):223-227. PubMed ID: 33078527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation.
    Dunzendorfer-Matt T; Mercado EL; Maly K; McCormick F; Scheffzek K
    Proc Natl Acad Sci U S A; 2016 Jul; 113(27):7497-502. PubMed ID: 27313208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autism Spectrum Disorder Symptom Profile Across the RASopathies.
    Geoffray MM; Falissard B; Green J; Kerr B; Evans DG; Huson S; Burkitt-Wright E; Garg S
    Front Psychiatry; 2020; 11():585700. PubMed ID: 33519543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Social behavior in RASopathies and idiopathic autism.
    Foy AMH; Hudock RL; Shanley R; Pierpont EI
    J Neurodev Disord; 2022 Jan; 14(1):5. PubMed ID: 35021989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of early communicative behavior in mouse models of neurofibromatosis type 1.
    Maloney SE; Chandler KC; Anastasaki C; Rieger MA; Gutmann DH; Dougherty JD
    Autism Res; 2018 Jan; 11(1):44-58. PubMed ID: 28842941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spred1, a negative regulator of Ras-MAPK-ERK, is enriched in CNS germinal zones, dampens NSC proliferation, and maintains ventricular zone structure.
    Phoenix TN; Temple S
    Genes Dev; 2010 Jan; 24(1):45-56. PubMed ID: 20047999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One
    Pacot L; Burin des Roziers C; Laurendeau I; Briand-Suleau A; Coustier A; Mayard T; Tlemsani C; Faivre L; Thomas Q; Rodriguez D; Blesson S; Dollfus H; Muller YG; Parfait B; Vidaud M; Gilbert-Dussardier B; Yardin C; Dauriat B; Derancourt C; Vidaud D; Pasmant E
    Genes (Basel); 2019 Aug; 10(9):. PubMed ID: 31443423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype.
    Pasmant E; Sabbagh A; Hanna N; Masliah-Planchon J; Jolly E; Goussard P; Ballerini P; Cartault F; Barbarot S; Landman-Parker J; Soufir N; Parfait B; Vidaud M; Wolkenstein P; Vidaud D; France RN
    J Med Genet; 2009 Jul; 46(7):425-30. PubMed ID: 19366998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SPRED1 Interferes with K-ras but Not H-ras Membrane Anchorage and Signaling.
    Siljamäki E; Abankwa D
    Mol Cell Biol; 2016 Oct; 36(20):2612-25. PubMed ID: 27503857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.
    Sharma R; Wu X; Rhodes SD; Chen S; He Y; Yuan J; Li J; Yang X; Li X; Jiang L; Kim ET; Stevenson DA; Viskochil D; Xu M; Yang FC
    Hum Mol Genet; 2013 Dec; 22(23):4818-28. PubMed ID: 23863460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SPRED1 mutations (Legius syndrome): another clinically useful genotype for dissecting the neurofibromatosis type 1 phenotype.
    Spurlock G; Bennett E; Chuzhanova N; Thomas N; Jim HP; Side L; Davies S; Haan E; Kerr B; Huson SM; Upadhyaya M
    J Med Genet; 2009 Jul; 46(7):431-7. PubMed ID: 19443465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.